PMID- 36520408
OWN - NLM
STAT- MEDLINE
DCOM- 20230405
LR  - 20230411
IS  - 2629-3277 (Electronic)
IS  - 2629-3269 (Print)
IS  - 2629-3277 (Linking)
VI  - 19
IP  - 3
DP  - 2023 Apr
TI  - The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells 
      for the Treatment of Premature Ovarian Failure.
PG  - 651-666
LID - 10.1007/s12015-022-10493-y [doi]
AB  - Premature ovarian failure (POF) affects 1% of women under 40, leading to 
      infertility. The clinical symptoms of the POF include hypoestrogenism, lack of 
      mature follicles, hypergonadotropinism, and amenorrhea. POF can be caused due to 
      genetic defects, autoimmune illnesses, and environmental factors. The 
      conventional treatment of POF remains a limited success rate. Therefore, an 
      innovative treatment strategy like the regeneration of premature ovaries by using 
      human umbilical cord mesenchymal stem cells (hUC-MSCs) can be a choice. To 
      summarize all the theoretical frameworks for additional research and clinical 
      trials, this review article highlights all the results, pros, and cons of the 
      hUC-MSCs used to treat POF. So far, the data shows promising results regarding 
      the treatment of POF using hUC-MSCs. Several properties like relatively low 
      immunogenicity, multipotency, multiple origins, affordability, convenience in 
      production, high efficacy, and donor/recipient friendliness make hUC-MSCs a good 
      choice for treating basic POF. It has been reported that hUC-MSCs impact and 
      enhance all stages of injured tissue regeneration by concurrently stimulating 
      numerous pathways in a paracrine manner, which are involved in the control of 
      ovarian fibrosis, angiogenesis, immune system modulation, and apoptosis. 
      Furthermore, some studies demonstrated that stem cell treatment could lead to 
      hormone-level restoration, follicular activation, and functional restoration of 
      the ovaries. Therefore, all the results in hand regarding the use of hUC-MSCs for 
      the treatment of POF encourage researchers for further clinical trials, which 
      will overcome the ongoing challenges and make this treatment strategy applicable 
      to the clinic in the near future.
CI  - (c) 2022. The Author(s).
FAU - Umer, Amna
AU  - Umer A
AD  - R3 Medical and Research Institute Pvt. Ltd, Jahangir Multiplex, H-13 Sector, 
      Islamabad, 44000, Pakistan.
FAU - Khan, Nasar
AU  - Khan N
AUID- ORCID: 0000-0002-9196-9321
AD  - R3 Medical and Research Institute Pvt. Ltd, Jahangir Multiplex, H-13 Sector, 
      Islamabad, 44000, Pakistan. nkhan@r3stemcell.com.
AD  - R3 Medical Research LLC, 10045 East Dynamite Boulevard Suite 260, Scottsdale, AZ, 
      85262, USA. nkhan@r3stemcell.com.
FAU - Greene, David Lawrence
AU  - Greene DL
AD  - R3 Medical and Research Institute Pvt. Ltd, Jahangir Multiplex, H-13 Sector, 
      Islamabad, 44000, Pakistan.
AD  - R3 Medical Research LLC, 10045 East Dynamite Boulevard Suite 260, Scottsdale, AZ, 
      85262, USA.
FAU - Habiba, Umm E
AU  - Habiba UE
AD  - R3 Medical and Research Institute Pvt. Ltd, Jahangir Multiplex, H-13 Sector, 
      Islamabad, 44000, Pakistan.
FAU - Shamim, Sabiha
AU  - Shamim S
AD  - R3 Medical and Research Institute Pvt. Ltd, Jahangir Multiplex, H-13 Sector, 
      Islamabad, 44000, Pakistan.
FAU - Khayam, Asma Umer
AU  - Khayam AU
AD  - Department of Biochemistry, Quaid e Azam University, Islamabad, 44000, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221215
PL  - United States
TA  - Stem Cell Rev Rep
JT  - Stem cell reviews and reports
JID - 101752767
SB  - IM
MH  - Humans
MH  - Female
MH  - *Primary Ovarian Insufficiency/therapy/etiology
MH  - *Mesenchymal Stem Cell Transplantation/methods
MH  - Umbilical Cord
MH  - *Mesenchymal Stem Cells
PMC - PMC10070285
OTO - NOTNLM
OT  - Human Umbilical Cord
OT  - Infertility
OT  - Mesenchymal Stem Cells
OT  - Ovarian Function
OT  - Premature Ovarian Failure
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/12/16 06:00
MHDA- 2023/04/05 06:42
PMCR- 2022/12/15
CRDT- 2022/12/15 11:21
PHST- 2022/12/10 00:00 [accepted]
PHST- 2023/04/05 06:42 [medline]
PHST- 2022/12/16 06:00 [pubmed]
PHST- 2022/12/15 11:21 [entrez]
PHST- 2022/12/15 00:00 [pmc-release]
AID - 10.1007/s12015-022-10493-y [pii]
AID - 10493 [pii]
AID - 10.1007/s12015-022-10493-y [doi]
PST - ppublish
SO  - Stem Cell Rev Rep. 2023 Apr;19(3):651-666. doi: 10.1007/s12015-022-10493-y. Epub 
      2022 Dec 15.